H2 tag- SEO Purpose
DPO: Rendering More Dialysis Patients with Higher Hb Levels, CKD: Chronic kidney disease; CV: Cardiovascular; DPO: Darbepoetin Alfa; ESA: Erythropoiesis-stimulating agent; IV: intravenous; Hb: Hemoglobin; SC: Subcutaneous.
23%–36% reduction in ESA costs per patient.
Estimated 230 hours saved per dialysis center per year.
- Comparable efficacy with both i.v. and s.c. administration routes with Darbepoetin Alfa in dialysis patients.
- 25% dose reduction observed when switching from Epoetin to Darbepoetin Alfa.
- Darbepoetin Alfa in dialysis patients has potential for reduced ESA-associated CV risk due to lower total doses.